Outbreak of Carbapenemase-Producing Klebsiella pneumoniae Blood Stream Infections in Neonatal Intensive Care Unit

Kaur, Jaspal; Sheemar, Sheevani; Chand, Kailash; Chopra, Shashi; Mahajan, Gomty

doi:10.20546/ijcmas.2016.501.073

Cited by 9 publications

(3 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbapenem resistant Klebsiella pneumoniae is associated with high morbidity and mortality and the treatment options have been further narrowed down to polymyxins, which can be prevented by the judicious use of carbapenems (Kaur et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Characterization and Antibiogram of Klebsiellae Isolated from Clinical Samples

A¹,

Karnaker²,

Rai³

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Characterization and Antibiogram of Klebsiellae Isolated from Clinical Samples

A¹,

Karnaker²,

Rai³

2017

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

“…Carbapenem-resistant Kp (CR-Kp) are now commonly encountered in hospitals worldwide. Outbreaks occur with increasing frequency; − strains spread quickly and cause high morbidity and mortality. Most clinical CR-Kp isolates contain a dominant strain, sequence type 258 (ST258), that expresses Kp carbapenemase.…”

Section: Introductionmentioning

confidence: 99%

Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach

Seeberger

2021

Chem. Rev.

132

View full text Add to dashboard Cite

The glycocalyx, a thick layer of carbohydrates, surrounds the cell wall of most bacterial and parasitic pathogens. Recognition of these unique glycans by the human immune system results in destruction of the invaders. To elicit a protective immune response, polysaccharides either isolated from the bacterial cell surface or conjugated with a carrier protein, for T-cell help, are administered. Conjugate vaccines based on isolated carbohydrates currently protect millions of people against Streptococcus pneumoniae , Haemophilus influenzae type b, and Neisseria meningitides infections. Active pharmaceutical ingredients (APIs) are increasingly discovered by medicinal chemistry and synthetic in origin, rather than isolated from natural sources. Converting vaccines from biologicals to pharmaceuticals requires a fundamental understanding of how the human immune system recognizes carbohydrates and could now be realized. To illustrate the chemistry-based approach to vaccine discovery, I summarize efforts focusing on synthetic glycan-based medicinal chemistry to understand the mammalian antiglycan immune response and define glycan epitopes for novel synthetic glycoconjugate vaccines against Streptococcus pneumoniae , Clostridium difficile , Klebsiella pneumoniae , and other bacteria. The chemical tools described here help us gain fundamental insights into how the human system recognizes carbohydrates and drive the discovery of carbohydrate vaccines.

show abstract

“…The carbapenem resistance of K. pneumoniae is a major reason for the strain's high morbidity and mortality. 10 Hence, studying the characteristics that promote resistance in this strain will promote the effective use of antibiotics in treatment. Moreover, studying antibioticresistant K. pneumoniae elucidates the importance of screening and confirmatory methods for research and treatment.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic Resistance of Clinical Klebsiella Isolates from Tertiary Care Hospital

Sivaramakrishnan¹,

Leela²,

Ravi³

et al. 2022

J. Pure Appl. Microbiol.

View full text Add to dashboard Cite

Klebsiella is a pathogen that causes a significantly high number of community-acquired and hospital-acquired infections, with infections being one of the leading causes of death in ICU patients worldwide due to increasing antibiotic-resistance and a lack of therapeutic options. A total of 230 Klebsiella spp. were collected from various clinical samples. After initial identification, the drug-resistant strain was subjected to standard Clinical Laboratory and Standards Institute methods such as Kirby–Bauer disc diffusion. All isolates were screened and confirmed for ESBL/AmpC β-lactamase/carbapenemase production. The isolated Klebsiella spp. were found to be K. pneumonia (89%), K. oxytoca (6.5%), and K. aerogenes (4.5%). Among the 230 isolates, 80 (34.7%) isolates were found to be ESBL producers via screening; of these, 53 (23.5%) were verified by a confirmatory test. Moreover, 115 isolates (50%) were screened as AmpC producers; of these, 23 isolates (10%) were verified by a confirmatory test. Carbapenemase producers accounted for 69 (30%) isolates, identified by screening; 25 (10.86%) were verified by a confirmatory test. ESBL producers accounted for the majority of Klebsiella spp. isolates, followed by carbapenem and AmpC producing strains.

show abstract

Outbreak of Carbapenemase-Producing Klebsiella pneumoniae Blood Stream Infections in Neonatal Intensive Care Unit

Cited by 9 publications

References 12 publications

Characterization and Antibiogram of Klebsiellae Isolated from Clinical Samples

Characterization and Antibiogram of Klebsiellae Isolated from Clinical Samples

Discovery of Semi- and Fully-Synthetic Carbohydrate Vaccines Against Bacterial Infections Using a Medicinal Chemistry Approach

Antibiotic Resistance of Clinical Klebsiella Isolates from Tertiary Care Hospital

Contact Info

Product

Resources

About